Life Science Nation Newsletter  | November 9,  2017  |  Issue 239

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Nov. 2  - Nov. 8)
Invests in Early-Stage Novel CNS and Oncology Therapies
Seeks Global Life Science Opportunities
Looking for Healthcare Opportunities with Focus on Senior Care
Raising New Fund to Invest in Medtech, Digital Health, and Late-Stage Therapeutics
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Natasha Eldridge, Director of RESI Conference Series, LSN

We're counting down the days to the first RESI NYC event on November 15th, and it's now time for LSN to present the RESI NYC Program Guide. This RESI event draws upon both the rising biotech ecosystem in New York and also LSN's global network of investors and major strategic movers in the life science space, and in the Program Guide you can find speakers, sponsors, and innovators from all over the world. To check out the full RESI NYC content and lineup, view the Program Guide below.

By Claire Jeong, Research Analyst, LSN

With RESI New York City less than a week away, we are excited to announce the Big Pharma panel. Large pharmaceutical companies are constantly searching for early-stage external innovations across a broad range of indications that address significant unmet medical need. Although there is a high level of risk and uncertainty associated with partnering with early-stage companies, the potential for enormous payouts continues to draw the attention of big pharma. Earlier this year, LSN had taken a close look at licensing deals in 2016 and concluded that most deals were pre-clinical. Despite this growing trend, establishing a relationship with these groups still present as a challenge for many entrepreneurs. Who do they reach out to? What is the process like? What can they expect?

In the Big Pharma panel, 5 senior-level executives from top pharmaceutical companies will discuss how they scout for external innovations and present a clear view of their unique strategies. The panelists include the following:
  • Joseph Simeone, Director, Enabling Technologies, Business Development & Licensing, Merck Research Labs, Merck
  • Anders Linden, Senior Manager, Business Analytics & Transactions, Johnson & Johnson Innovation
  • Sree Kant, Executive Director, Strategy, External R&D Innovation, Pfizer
  • Shiv Krishnan, Senior Director, Head, Partnering, External Sciences & Innovation, Global BioTherapeutics, Sanofi
  • Monica Cheng, Business Development & Licensing/Prescription Medicine - Cardiometabolic, Boehringer Ingelheim
Meet RESI NYC's Investors & Strategics
By Cole Bunn, Senior Research Analyst, LSN

Whether you're looking to identify your lead investor, fill out a round of funding or explore strategic partnerships, RESI has a robust pool of groups you should be speaking with. As we approach our first ever RESI conference to be held in New York City, we're pleased to have everything from government organizations and philanthropic venture groups to leading pharmaceutical companies and venture funds represented, all looking for novel technologies and great entrepreneurs. Have a look at some of the folks you can meet.

QuickFire Challenge
I n honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics